Bristol-Myers Squibb (BMY) DIvidends Date & History

Key Takeaways

• BMY offers a current dividend yield near 4.00% with quarterly payments of $0.63 per share.
• The company has raised its dividend for 19 consecutive years, supporting long-term growth.
• Payout ratio remains sustainable at approximately 39% to 55% of earnings.
• Strong free cash flow provides solid coverage for dividend payments.
• Yield exceeds many large-cap pharmaceutical peers, enhancing appeal for income-focused investors.
• Consistent quarterly schedule with upcoming ex-dividend date of October 2, 2026.

Dividend Overview

Bristol-Myers Squibb (BMY) maintains a quarterly dividend policy, distributing $0.63 per share four times annually for a total of $2.52. This results in a yield of approximately 4.00% based on recent share prices around $63. The company is positioned as a dividend growth stock rather than a high-yield play, with modest annual increases that have supported steady income for shareholders. Payments follow a regular schedule, with the next ex-dividend date set for October 2, 2026, and payment on November 2, 2026.

Dividend History and Growth

BMY has demonstrated consistent dividend growth, increasing payouts for 19 straight years. Recent adjustments include a rise from $0.60 to $0.62 per quarter in late 2024 and early 2025, followed by a further lift to $0.63 in 2026. This reflects a measured strategy of annual or periodic increases aligned with earnings stability. The firm has avoided cuts even amid patent expirations on legacy products, underscoring a long-term commitment to returning capital to shareholders through reliable dividend growth.

Dividend Sustainability and Payout Ratio

The dividend appears sustainable given a payout ratio of roughly 39% to 55% of earnings and strong free cash flow coverage exceeding 40% in recent periods. Trailing twelve-month free cash flow reached approximately $11.4 billion, comfortably supporting annual dividend obligations near $5.1 billion. Low debt levels relative to cash generation and diversified revenue from key products further bolster resilience. While earnings can fluctuate with product cycles, cash flow metrics indicate the current dividend is well-covered without straining operations.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, BMY’s yield of about 4.00% stands above several large-cap peers such as Johnson & Johnson (around 1.9%) and Merck (around 2.3%), though it trails Pfizer’s higher yield near 6.2%. Compared to the broader healthcare industry average of roughly 1.4%, BMY provides an above-average income profile. Its growth track record also compares favorably, offering a balance of yield and increases that many competitors lack.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover similar opportunities.

Is This Stock Attractive for Dividend Investors?

BMY may appeal to income-oriented investors seeking a yield above many healthcare peers combined with a proven history of annual increases. Dividend growth investors could value the 19-year streak and conservative payout ratio, which leaves room for future raises. Conservative or long-term holders might appreciate the robust free cash flow backing and sector stability, though they should note exposure to patent cliffs and product transitions common in pharmaceuticals. The stock suits those prioritizing reliable quarterly income over aggressive growth, provided they monitor earnings coverage and pipeline developments. This analysis is for informational purposes only and does not constitute investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations